Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer San Diego, CA – Fate Therapeutics, Inc. announced today that Christian Weyer, M.D., M.A.S. has been appointed President and Chief Executive Officer and elected to the Company’s Board of Directors, Read All » View HTML
Toggle Summary San Diego, CA  – Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. Read All » View HTML
Toggle Summary San Diego, CA – Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer. Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May Read All » View HTML
Toggle Summary Data Support the Potential Benefit of a Novel Ex Vivo Cell Modulation Approach to Improving Engraftment in Patients Undergoing Umbilical Cord Blood Transplantation Read All » View HTML
Toggle Summary U.S. Patent Covers Key Compositions Used in the Generation of Human Induced Pluripotent Stem Cells Read All » View HTML
Toggle Summary Secures U.S. Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells Read All » View HTML
Toggle Summary Joins Strategic Investor Syndicate of Fate that Includes Four Pharmaceutical Companies Read All » View HTML
Toggle Summary Fate Therapeutics announces encouraging clinical results and change in management San Diego, CA – February 21, 2011 – In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics Read All » View HTML
Toggle Summary Encouraging Phase 1b Clinical Data Presented at 2011 BMT Tandem Meetings Read All » View HTML
Toggle Summary San Diego, CA and Ottawa, Canada (October 14, 2010) – Fate Therapeutics, Inc. has forged a collaboration and license agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, through its BD Biosciences segment, for the joint development and worldwide Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.